Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2003 1
2004 1
2006 2
2008 1
2009 1
2013 1
2014 1
2015 1
2020 1
2021 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of head and neck cancers: issues for clinical pharmacists.
Scarpace SL, Brodzik FA, Mehdi S, Belgam R. Scarpace SL, et al. Pharmacotherapy. 2009 May;29(5):578-92. doi: 10.1592/phco.29.5.578. Pharmacotherapy. 2009. PMID: 19397465 Review.
Head and neck cancers are a heterogeneous group of diseases involving the oral cavity, pharyngeal tube, and larynx. Given the drug therapy options available, clinical pharmacists can play an important role in the care of this patient population. ...Cis …
Head and neck cancers are a heterogeneous group of diseases involving the oral cavity, pharyngeal tube, and larynx. Given the drug …
Comparative Treatment Outcome in T3N0 Glottic Cancer With and Without Vocal Fold Fixation Receiving Radiation Therapy and Concurrent Low-Dose Intra-Arterial Cisplatin Infusion.
Ono T, Tanaka N, Chitose SI, Tanoue S, Kurita T, Sueyoshi S, Fukahori M, Miyata Y, Muraki K, Tsuji C, Ogo E, Hattori C, Sato K, Abe T, Umeno H. Ono T, et al. Ann Otol Rhinol Laryngol. 2022 Aug;131(8):897-904. doi: 10.1177/00034894211047789. Epub 2021 Sep 25. Ann Otol Rhinol Laryngol. 2022. PMID: 34565187
Additionally, the 3-year freedom from laryngectomy, laryngectomy-free survival, and laryngo-esophageal dysfunction-free survival rates of patients with or without VFF were 94.4% and 86.7%, 88.9% and 73.3%, and 83.3% and 73.3%, respectively. Grade …
Additionally, the 3-year freedom from laryngectomy, laryngectomy-free survival, and laryngo-esophageal dysfunction-free survival rate …
Risk factors for oral mucositis in patients with solid tumors under treatment with cetuximab: a retrospective cross-sectional study.
Martins JO, Borges MM, Malta CE, Guerra JM, Crispim AA, Coelho BC, Silva LF, Silva PG. Martins JO, et al. Med Oral Patol Oral Cir Bucal. 2024 Mar 1;29(2):e248-e254. doi: 10.4317/medoral.26237. Med Oral Patol Oral Cir Bucal. 2024. PMID: 37992137 Free PMC article.
BACKGROUND: This study retrospectively analyzed the risk factors for oral mucositis (OM) during cetuximab treatment. MATERIAL AND METHODS: We screened patients using cetuximab and retrospectively evaluated the presence of OM based on medical records. ...The X2 test and mul …
BACKGROUND: This study retrospectively analyzed the risk factors for oral mucositis (OM) during cetuximab treatment. MATERIAL AND MET …
Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma.
Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Vera-Llonch M, et al. Cancer. 2006 Jan 15;106(2):329-36. doi: 10.1002/cncr.21622. Cancer. 2006. PMID: 16342066 Free article.
BACKGROUND: The current study was conducted to characterize the risks and clinical consequences of oral mucositis (OM) in patients with head and neck carcinoma (HNC) who are receiving radiation therapy. ...Information obtained included patient characteristics …
BACKGROUND: The current study was conducted to characterize the risks and clinical consequences of oral mucositis (OM) in pati …
Periostin in middle ear mucosa according to eosinophilic otitis media severity: Middle ear pathology-based treatment.
Esu Y, Masuda M, Yoshida N. Esu Y, et al. Auris Nasus Larynx. 2020 Aug;47(4):527-535. doi: 10.1016/j.anl.2020.05.014. Epub 2020 Jun 23. Auris Nasus Larynx. 2020. PMID: 32586742
We assessed serum periostin levels and expression of periostin in the middle ear mucosa according to three grade of EOM severity (grade1 to 3). METHODS: 68 patients of blood and serum samples were corrected by whom diagnose bilateral EOM in Jichi Medical University …
We assessed serum periostin levels and expression of periostin in the middle ear mucosa according to three grade of EOM severity (gra …
Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer.
Bhide SA, Ahmed M, Barbachano Y, Newbold K, Harrington KJ, Nutting CM. Bhide SA, et al. Br J Cancer. 2008 Jul 8;99(1):57-62. doi: 10.1038/sj.bjc.6604444. Epub 2008 Jun 17. Br J Cancer. 2008. PMID: 18560402 Free PMC article.
The dose of 5-FU was reduced in six patients and that of cisplatin in four patients. The incidence of grade 3/4 toxicity was: neutropenia 5%, thrombocytopenia 1%, nausea and vomiting 3%. ...Full-dose radiotherapy was administered to 98% of patients. The incid …
The dose of 5-FU was reduced in six patients and that of cisplatin in four patients. The incidence of grade 3/4 toxicity was: …
Endolaryngeal dilatation versus laryngotracheal reconstruction in the primary management of subglottic stenosis.
Günaydın RÖ, Süslü N, Bajin MD, Kuscu O, Yılmaz T, Ünal ÖF, Akyol U. Günaydın RÖ, et al. Int J Pediatr Otorhinolaryngol. 2014 Aug;78(8):1332-6. doi: 10.1016/j.ijporl.2014.05.022. Epub 2014 Jun 2. Int J Pediatr Otorhinolaryngol. 2014. PMID: 24961989
EDs were performed in 19 patients with 6 CKBDs, 7 LBDs and 6 BDs. There were 3 grade II, 13 grade III cases in the LTRCG group while 4 grade I, 6 grade II, 8 grade 3 and 1 grade 4 in the ED group. ...Restenosis rates were fo …
EDs were performed in 19 patients with 6 CKBDs, 7 LBDs and 6 BDs. There were 3 grade II, 13 grade III cases in the LTRC …
Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S, Yokota T, Onozawa Y, Ogawa H, Onoe T, Kamijo T, Iida Y, Nishimura T, Onitsuka T, Yasui H. Hamauchi S, et al. Jpn J Clin Oncol. 2015 Dec;45(12):1116-21. doi: 10.1093/jjco/hyv142. Epub 2015 Sep 29. Jpn J Clin Oncol. 2015. PMID: 26423341
The median age was 75 years (range, 54-82), male:female ratio, 24:1; performance status, 0-1 (23) or 2 (2); primary tumor site, oropharynx (10), hypopharynx (12), larynx (1) or oral cavity (2); Stage III (3), IVa (19) or IVb (3); induction chemotherapy, with …
The median age was 75 years (range, 54-82), male:female ratio, 24:1; performance status, 0-1 (23) or 2 (2); primary tumor site, oropharynx ( …
Tear function and ocular surface changes with topical mitomycin (MMC) treatment for primary corneal intraepithelial neoplasia.
Dogru M, Erturk H, Shimazaki J, Tsubota K, Gul M. Dogru M, et al. Cornea. 2003 Oct;22(7):627-39. doi: 10.1097/00003226-200310000-00007. Cornea. 2003. PMID: 14508259
Initial impression cytology specimens showed goblet cell loss, higher grades of squamous metaplasia, areas of isolated keratinized, binucleated, and actively mitotic disfigured epithelial cells in all patients. The mean goblet cell density and squamous metaplasia grade …
Initial impression cytology specimens showed goblet cell loss, higher grades of squamous metaplasia, areas of isolated keratinized, b …
Discomfort symptoms reduction and ocular surface parameters recovery with Artelac Rebalance treatment in mild-moderate dry eye.
Versura P, Profazio V, Giannaccare G, Fresina M, Campos EC. Versura P, et al. Eur J Ophthalmol. 2013 Jul-Aug;23(4):488-95. doi: 10.5301/ejo.5000267. Epub 2013 Mar 28. Eur J Ophthalmol. 2013. PMID: 23539457
Inclusion criteria were Ocular Surface Disease Index (OSDI) score >16, tear film break-up time (TFBUT) <10 seconds, Schirmer test I >10 mm/5 min, and mild ocular surface damage (Oxford grading) 3. Artelac Rebalance eyedrops were administered 3 times …
Inclusion criteria were Ocular Surface Disease Index (OSDI) score >16, tear film break-up time (TFBUT) <10 seconds, Schirmer test I &g …
14 results